Establishment of a Liver Transplant Patient-derived Tumor Xenograft (PDX) Model Using Cryopreserved Pancreatic Ductal Adenocarcinoma

Anticancer Res. 2020 May;40(5):2637-2644. doi: 10.21873/anticanres.14234.

Abstract

Background/aim: There is rapid progression and widespread use of patient-derived tumor xenografts (PDX) in translational pancreatic cancer research. This study aimed to establish a liver transplant PDX model using cryopreserved primary pancreatic ductal adenocarcinoma (PDAC).

Patients and methods: Primary PDAC from 10 patients were cryopreserved and transplanted into immunodeficient mice using the liver pocket method. H&E staining and immunohistochemical staining, such as Ki-67, p53, Smad4, and MUC1 were used to evaluate engraftment and histological similarities.

Results: Patient-derived xenograft placement was successful in six cases (60%), and 10 mice (33.3%). The Ki-67 index of primary PDAC and the cryopreservation duration were significantly related to successful engraftment (p=0.003 and p=0.007, respectively).

Conclusion: In this study, we succeeded in establishing a liver transplant PDX mouse model as a preclinical platform. The successful engraftment was affected by the cryopreservation duration and could be detected by the Ki-67 index.

Keywords: Xenograft model; cryopreservation; pancreatic ductal carcinoma.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Animals
  • Carcinoma, Pancreatic Ductal / pathology*
  • Cryopreservation*
  • Female
  • Humans
  • Liver Transplantation*
  • Male
  • Mice
  • Middle Aged
  • Pancreatic Neoplasms / pathology*
  • Xenograft Model Antitumor Assays*